EasiVits Acceptability & Tolerance Study

NCT07619170 | Active Not Recruiting

• 1 other identifier: NeoteriQ
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

In order to achieve metabolic stability, dietary treatment of inborn errors of metabolism (IEM) may require restriction of protein (e.g. phenylketonuria, tyrosinaemia, homocystinuria, organic acidaemias, maple syrup urine disease (MSUD), urea cycle disorders), fat (e.g. fatty acid oxidation disorders) or carbohydrate (e.g. glycogen storage disease). Manipulation of dietary intake potentially reduces micronutrient status, and provision of a comprehensive vitamin and mineral supplement may become an essential adjunct to dietary treatment. Paediatric Seravit and Frutivits are vitamin and mineral supplements that are currently available on prescription. Paediatric Seravit is designed for children between 1-3 years of age but has high amounts of added carbohydrate, restricting its use for patients with IEM with restricted carbohydrate intake. Fruitivits is designed for children over the age of 3 years and is orange flavoured, restricting patient's choice, potentially leading to poor adherence and taste fatigue. Previous studies show that despite improvements in some nutritional markers using the currently available vitamin and mineral supplements, overall use of the vitamin and mineral supplements was less than prescribed and alternatives are needed to guarantee delivery of micronutrients in children at risk of deficiencies as a result of an essential manipulation of diet in inborn disorders of metabolism. Whilst condition specific formula for IEM often contains added micronutrients, there are global concerns about over- and under-supplementation and the impact on palatability. Consequently, some health professionals advocate the availability of unfortified products to enable individualised tailoring of micronutrient intake using a separate vitamin and mineral supplement. Furthermore, with the advent of pharmacological treatments for some IEM, there is evidence that cessation of specialist formula without significant changes to dietary food intake, commonly leads to deficiencies in several micronutrients. EasiVits are new vitamin and mineral supplements which contain minimal carbohydrate and are unflavoured. This allows them to be used in carbohydrate restricted IEMs, and patients can also add their preferred flavours via permitted fruit cordials or drinks in order to potentially improve adherence and prevent taste fatigue.

Conditions

Inborn Errors of Metabolism

Outcome Measures

Primary Outcomes (3)

• Study Product Acceptability

  Acceptability measured using a non-validated questionnaire asking participants to rate their usual product (baseline) and the study product (end of study) in terms of appearance, smell, taste, texture, ease of mixing, ease of taking and aftertaste, using a 5-point Likert scale from Great to Terrible.

  7 days

• Gastrointestinal Tolerance of Study Product

  Gastrointestinal symptoms measured using a daily diary to record any episode of diarrhoea, constipation, bloating, nausea, vomiting, burping/regurgitation, flatulence or abdominal pain with a rating of none, mild, moderate or severe.

  7 days

• Study Product Adherence

  Adherence measured using a daily diary to record the amount of study product taken, how and when it was taken. This is then compared to the prescribed amount.

  7 days

Study Arms (2)

UNO EasiVits

EXPERIMENTAL

UNO EasiVits for 7 days

Dietary Supplement: UNO EasiVits

DUO EasiVits

EXPERIMENTAL

DUO EasiVits for 7 days

Dietary Supplement: DUO EasiVits

Interventions

UNO EasiVits DIETARY_SUPPLEMENT

7-day administration of UNO EasiVits

UNO EasiVits

DUO EasiVits DIETARY_SUPPLEMENT

7-day administration of DUO EasiVits

DUO EasiVits

Eligibility Criteria

• Age: 1 Year - 16 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Male and female IEM patients ages 1-16 years.
• Patients diagnosed with an IEM.
• Taking vitamin and mineral supplements for IEM and willing to take the new supplements for 7 days.
• Absence of comorbidities.
• Adherence with dietary management and vitamin and mineral supplements.
• Able to understand and comply with the requirements of the investigation and sign the Informed Consent Form/Assent form.

You may not qualify if:

• Age \<1 years old.
• Patients with comorbidities.
• Any moderate to severe acute illness which in the opinion of the Investigator would interfere with the study procedures or study outcome.
• History of poor co-operation, non-adherence with dietary management, or poor adherence to investigation procedures.
• Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Sponsors & Collaborators

• NeoteriQ Ltd.: lead
• Birmingham Children's Hospital: collaborator

Study Sites (1)

Birmingham Children's Hospital

Birmingham, B4 6NH, United Kingdom

Location

MeSH Terms

Conditions

Metabolism, Inborn Errors

Condition Hierarchy (Ancestors)

Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Anita MacDonald, PhD

  Birmingham Children's Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2026
• First Posted: June 1, 2026
• Study Start: March 7, 2026
• Primary Completion (Estimated): September 23, 2026
• Study Completion (Estimated): September 23, 2026
• Last Updated: June 1, 2026

Record last verified: 2026-05

Locations

GB (1)